1.Date of the shareholders' meeting resolution:2025/05/16

2.Name and title of the managerial officer with permission to engage in competitive conduct:
(1)Jui-Wen Wu；Director
(2)Lai-Shou Su；Director
(3)Min-Li Wei；Director
(4)Shih-Cheng Lai；Director

3.Items of competitive conduct in which the officer is permitted to engage:Similiar scope of business of director of management

4.Period of permission to engage in the competitive conduct:
The period of being director of the Company.

5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):
(1)4,540,822 in total voting rights were represented at the time of voting;
(2)4,540,822 voting right presented for, 100% of total voting rights;
(3)0 voting right presented against, 0% of total voting rights;
(4)0 invalid votes, 0% of total voting rights;
(5)0 voting right presented abstention and not voting,0% of total voting rights;
(6)This proposal was approved as proposed as affirmative rights higher than statutory ones.

6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below):
Jui-Wen Wu；Director

7.Company name of the mainland China enterprise and the officer’s position in the enterprise:
Worldco Biotech (Chengdu) Pharmaceutical Ltd.
Representative Supervisor of Worldco International Co., Ltd

8.Address of the mainland China enterprise:
Room 3~4, 7F., Unit 2, Jinniu Civic Center Building 1, No. 999, Yipin Tianxia Dajie, Jinniu Dist., Chengdu City, Sichuan Province

9.Operations of the mainland China enterprise:Sales of western drugs

10.Impact on the company’s finance and business:None.

11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:N/A

12.Any other matters that need to be specified:None.